癌痛灵栓剂治疗中重度癌症疼痛的临床观察

摘要

Objective To evaluate the efficacy of Aitongling Suppository (ATLS), a Traditional Chinese Medicine Formulation for treatment of moderate and severe cancer pain. Methods Before-after study in the same individual was used, 30 cancer pain with moderate or severe pain were divided into ATLS group and control ed group. The ATLS group was treated with ATLS (1# q12h pro rect), while the control ed group with MSCT (20mg q12h po). Both groups were given for 4 days. Pain intensity was assessed by NPIS (0~10 Numeric patients intensity scale), PID, SPID, PAR, TPAR, Rate of PAR over 2 grade and TANS were paramenters used for evaluating the analgesic effect . T-test and Chi-square test were used to evaluate the differences. Results PID of control ed group was superior to that of ATLS one at T0.25 in Day2, T0.5, T1 in Day3, and T0.5 in Day4 (P<0.05). 0 PAR rate of ATLS group was higher than that of control ed one at T0.5, in Day1, T10, T12 in Day2, T0, T0.25, T10 in Day3 (P<0.05). 1 PAR rate of ATLS group was lower than that of control ed one at T0.5, T12 in Day1, T10, T12 in Day2, T0.25 in Day3 and T0, T 0.25 in Day4 (P<0.05). Over Moderate Pain Rate of ATLS group was lower than that of control ed one at T0.5 in Day4 (P<0.05). Conclusions The clinical research suggested that the Analgesic efficacy of ATLS was same as that of MSCT in treatment of moderate and severe cancer pain, but the Taking-effect time was longer in ATLS group than in MSCT one.%目的：评价癌痛灵栓剂对中重度癌症疼痛的镇痛作用。方法采用自身对照的方法，共观察30例伴有中重度癌症疼痛的恶性肿瘤患者，研究分为试验组和对照组，试验组用癌痛灵栓剂，1粒，q12h，纳肛；对照组用硫酸吗啡控释片，20m g，q12h，口服。均连续用药4天。观察其疼痛强度差、总疼痛强度差、疼痛缓解度、总疼痛缓解度、中度以上疼痛缓解率、总镇痛分等项镇痛评价指标。以t检验和χ2检验进行统计分析。结果用药者在D2的T0.25、D3的T0.5、T1和D4的T0.5时点其疼痛强度差显示硫酸吗啡控释片组优于癌痛灵栓剂组(P＜0.05)。在D1的T0.5、D2的T10、T12和D3的T0、T0.25、T10时点癌痛灵栓剂组的疼痛未缓解的人数所占比，较硫酸吗啡控释片组多(P＜0.05)。在D1的T0.5、T12、D2的T10、T12和D3的T0.25和D4的T0、T0.25时点癌痛灵栓剂组的疼痛轻度缓解的人数所占比，较硫酸吗啡控释片组少(P＜0.05)。在D4的T0.5时点的癌痛灵栓剂组中度缓解的人数所占比，较硫酸吗啡控释片组少(P＜0.05)。结论癌痛灵栓剂在治疗中重度癌症疼痛方面其与硫酸吗啡控释片（20mg）大致相当，用药安全，但起效时间较慢。